Filtered By:
Source: Journal of the American Society of Nephrology : JASN
Drug: Coumadin
Therapy: Dialysis
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 1 results found since Jan 2013.
Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients
It is unclear whether warfarin is protective or harmful in patients with ESRD and atrial fibrillation. This state of equipoise raises the question of whether alternative anticoagulants may have a therapeutic role. We aimed to determine apixaban pharmacokinetics at steady state in patients on hemodialysis. Seven patients received apixaban 2.5 mg twice daily for 8 days. Blood samples were collected before and after apixaban administration on days 1 and 8 (nondialysis days). Significant accumulation of the drug was observed between days 1 and 8 with the 2.5-mg dose. The area under the concentration-time curve from 0 to 24 hou...
Source: Journal of the American Society of Nephrology : JASN - June 30, 2017 Category: Urology & Nephrology Authors: Mavrakanas, T. A., Samer, C. F., Nessim, S. J., Frisch, G., Lipman, M. L. Tags: Clinical Research Source Type: research
